Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2334778 | 0.90 | LMNA (0.41) | ALDH1A1KDM4ELMNASMN1; SMN2TSHR | |
| SCHEMBL2338966 | 0.90 | MEN1 (0.42) | ALDH1A1LMNASMN1; SMN2TSHRHTT | |
| SCHEMBL2332019 | 0.90 | HIF1A (0.45) | ALDH1A1LMNASMN1; SMN2TSHRHTT | |
| SCHEMBL2338098 | 0.89 | ALDH1A1 (0.40) | ALDH1A1LMNASMN1; SMN2TSHRHTT | |
| SCHEMBL2337909 | 0.89 | ALDH1A1 (0.44) | ALDH1A1LMNASMN1; SMN2TSHRHTT | |
| SCHEMBL2335244 | 0.89 | TP53 (0.44) | ALDH1A1LMNASMN1; SMN2TAS2R14HPGD | |
| SCHEMBL2341038 | 0.89 | ALDH1A1 (0.40) | ALDH1A1LMNASMN1; SMN2TSHRHTT | |
| SCHEMBL2333362 | 0.89 | HIF1A (0.46) | ALDH1A1LMNASMN1; SMN2TSHRHTT | |
| SCHEMBL2339713 | 0.88 | MEN1 (0.41) | ALDH1A1LMNASMN1; SMN2TSHRHTT | |
| SCHEMBL2335273 | 0.88 | PDE4A (0.54) | ALDH1A1LMNASMN1; SMN2TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270902-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | claimed |
| EP-2360142-A1 | N-substituted benzene sulfonamides | Elan Pharmaceuticals Inc. (US) | 2011-08-24 | — | — | EP | claimed |
| US-20050245573-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. | 2005-11-03 | — | — | US | claimed |
| US-20120270902-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8193389-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2374792-A1 | N-substituted benzene sulfonamides | Elan Pharmaceuticals Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2360142-A1 | N-substituted benzene sulfonamides | Elan Pharmaceuticals Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20050245573-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245573-A1 | N-substituted benzene sulfonamides | PSEN1, PSEN2, BCHE | ALDH1A1 665/4885KDM4E 1403/4885LMNA 3051/4885 |
| US-20120270902-A1 | N-substituted benzene sulfonamides | PSEN1, PSEN2, BCHE | ALDH1A1 665/4885KDM4E 1403/4885LMNA 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.